U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489651) titled 'RE104 Safety and Efficacy Study in Generalized Anxiety Disorder' on March 18.
Brief Summary: The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Generalized Anxiety Disorder
Intervention:
DRUG: RE104 for Injection
Single, subcutaneous dose of RE104 for Injection
DRUG: Placebo
Single, subcutaneous dose of 0.9% sodium chloride for injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Reunion Neuroscience ...